This study by Schjoldager et al. (AJOG, 2017) sought to determine if treating the placenta site with recombinant factor VII (rFVIIa) after removal of placenta following placenta previa decreases PPH with affecting intravascular coagulation.
5 cases booked for cesarean section for placenta previa were prospectively evaluated.
rFVIIa (1 mg/246 ml) was applied to the placental bed via soaked swab following delivery and placental removal. The surgeon repeated the procedure if the first application was not effective. Hemoglobin concentration, platelet count, INR, APTT, fibrinogen and factor VII were tested in peripheral blood before and after removal of the placenta. These blood variables were also tested in women undergoing planned C-sections without previa. In all of the cases median blood loss was 490 ml (range 300-800). No negative effects were seen from the rFVIIa, and it did not enter the circulation. No changes in coagulation parameters were found.
Topical application of recombinant activated factor VII during cesarean section for placenta previa
Please log in to access OBGFirst and the 2T Ultrasound Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
